MPN | Tumor

CURE’s myeloproliferative neoplasms (MPN) page is an extensive resource of cancer information featuring the latest MPN news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on myeloproliferative neoplasms.

Educated Patient® MPN Summit Clinical Trials Presentation: May 7, 2022

May 20th 2022

Watch Kapila Viges, from the MPN Research Foundation, discuss clinical trials, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Novel Agents and Clinical Trials in Polycythemia Vera Presentation: May 7, 2022

May 19th 2022

Watch Dr. Angela Fleishman, from the University of California Irvine, discuss novel agents and clinical trials in polycythemia vera, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Diagnoses and Treatment Panel: May 7, 2022

May 18th 2022

Watch Dr. Jamile Shammo, Dr. Aaron Gerds and Dr. Bart Scott, answer questions during the diagnoses and treatment panel during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Current Treatment Options Presentation: May 7, 2022

May 17th 2022

Watch Dr. Bart Scott, from Fred Hutchinson Cancer Center, discuss current treatment options, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Approach to Diagnosing & Assessing Symptoms Presentation: May 7, 2022

May 16th 2022

Watch Dr. Aaron Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss approaches to diagnosing and assessing symptoms, during the CURE Educated Patient MPN Summit.

10-Year-Old Child With Cancer Sworn in as Honorary Member of NYPD, Experts Suggest a New Name for Certain Prostate Cancers and More

April 22nd 2022

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

Healthy Pregnancy Is ‘Definitely’ Possible for Women With MPNs

April 18th 2022

Patients with myeloproliferative neoplasms, a group of blood cancers, who plan to conceive should talk with their doctor about their obstetric and medical history and risk of complications, according to an expert.

Highlights and Key Takeaways from the 2021 MPN Roundtable

March 14th 2022

Cancer Advocacy Helps Ease Nerves and Uncertainty, Says One Patient

March 14th 2022

A patient’s experience with polycythemia vera — a rare blood cancer — led to her becoming an advocate for others to help ease all the nerves and uncertainty that many patients face when they hear they have cancer.

FDA's Approval of Besremi Marks 'One of the Most Important Developments' in Treatment of Polycythemia Vera

March 10th 2022

Recently approved, by the Food and Drug Administration, Besremi has demonstrated to be effective and safe for patients with polycythemia vera — adding hope to their treatment regimen.

FDA Grants Accelerated Approval to Vonjo for Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

The Food and Drug Administration’s greenlight of Vonjo marks the first approved therapy to address the needs of patients with cytopenic myelofibrosis, a type of myeloproliferative neoplasm.

Expert Emphasizes Importance of Integrative Care, Well-Being in Long-Term Care of MPNs

February 24th 2022

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about the long-term care of MPNs.

Improving Overall Care of MPNs with Support Groups and Advocacy Research

February 24th 2022

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about MPN resources and support groups available to patients and loved ones.

Taking an Active Voice in MPN Treatment to Improve Communication About Care

February 24th 2022

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Shireen Sirhan, from the Jewish General Hospital-McGIll University, about patients being their own best advocate in their MPN care.

Expert Emphasizes Importance of Finding Specialized Multidisciplinary Team to Treat MPNs

February 24th 2022

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Shireen Sirhan, from the Jewish General Hospital-McGIll University, about finding a care team that specializes in MPNs.

Caring for the Caregiver: Expert Emphasizes Loved Ones of Patients with MPNs Shouldn’t Take This Role on Alone

February 24th 2022

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about the role of caregivers after an MPN diagnosis.

Quality of Life, Outcomes After Stem Cell or Bone Marrow Transplant May Be Similar Regardless of Patient’s Relation to Donor

February 15th 2022

Patients with cancer who receive bone marrow or stem cells from either a related or unrelated donor may experience similar outcomes and quality of life post transplant, which may highlight the efforts made by teams to help patients along the way.

Advancements in Rare Blood Cancer Have ‘Changed the Way We Treat Every Cancer’, Expert Says

February 11th 2022

A blood cancer specialist discusses how the development of tyrosine kinase inhibitors in the 1990s to treat chronic myelogenous leukemia drove major oncology advancements over the next three decades.

Momelotinib ‘Stands On Its Own’ Compared With Other JAK Inhibitors for Myelofibrosis

January 31st 2022

For patients with myelofibrosis, previously treated with Jakafi, momelotinib could be a major drug approval coming up, according to an expert.

LeVar Burton Gives ‘Voice and Visibility’ to Patients with MPNs Through Storytelling and Advocacy

December 20th 2021

When storytelling becomes a part of one’s identity, it can benefit a wide group of people — such as the MPN community — to share a potentially lifesaving message, according to LeVar Burton.

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

December 16th 2021

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

MPN Heroes® Recognition Program 2021

December 10th 2021

Watch the entire MPN Heroes® Recognition Program here!

CURE® Celebrates Eight Individuals’ Contributions at the 9th Annual MPN Heroes Program

December 9th 2021

CURE®’s ninth annual MPN Heroes Program recognized the heroes who go above and beyond to support patients with the disease.

LeVar Burton Discusses the Power of Storytelling in Health Care

December 2nd 2021

LeVar Burton, most noted for his roles in “Reading Rainbow” and “Star Trek”, stresses how important storytelling is — both in everyday life and in health care settings.

FDA Approves Besremi for Polycythemia Vera

November 13th 2021

The Food and Drug Administration granted approval to Besremi for the treatment of adults with polycythemia vera.

To Transplant or Not? Myelofibrosis Scoring Systems Help Decide

November 8th 2021

Patients should understand the different prognostic scoring systems used in myelofibrosis, and how the results can impact treatment decisions.

Healthy Pregnancy Is Possible With an MPN Diagnosis

October 27th 2021

Women with a myeloproliferative neoplasm can have healthy pregnancies, as long as they coordinate their care and know what to look out for.

Becoming an Informed Patient With Rare Cancer

October 25th 2021

Dr. Gabriela Hobbs offers insight into a rare cancer, myeloproliferative neoplasms, to help patients learn more during their treatment journey.

Informed Patients Have a ‘Realistic and Honest’ Relationship with their MPN Disease

October 1st 2021

Keeping track of labs can help patients with MPN better understand the side effects and reasons for treatment , according to an expert from the Medical College of Wisconsin.

Expert Is ‘Optimistic’ About MPN Treatment Progress

September 23rd 2021

Patients who are living with MPN should live a healthy lifestyle and not compare their disease to others, because of variability between mutations, according to an expert.